Last update 21 Nov 2024

Vocimagene amiretrorepvec

Overview

Basic Info

Drug Type
Gene therapy
Synonyms
Flucytosine prodrug activating therapy, RRV, Retroviral replicating viral
+ [10]
Target
Mechanism
CDA modulators(Cytidine deaminase modulators)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationPRIME (EU), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10328--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GlioblastomaDiscovery
IL
30 Nov 2015
GlioblastomaDiscovery
KR
30 Nov 2015
GlioblastomaDiscovery
US
30 Nov 2015
GlioblastomaDiscovery
CA
30 Nov 2015
Glioblastoma MultiformeDiscovery
CA
30 Nov 2015
Glioblastoma MultiformeDiscovery
US
30 Nov 2015
Glioblastoma MultiformeDiscovery
KR
30 Nov 2015
Glioblastoma MultiformeDiscovery
IL
30 Nov 2015
Recurrent Malignant GliomaDiscovery
US
30 Nov 2015
Recurrent Malignant GliomaDiscovery
IL
30 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
usklpczbsp(cfuxmcnqya) = ztksxsitwb vnqoeocqbe (cjshpyjlvy )
-
01 May 2023
usklpczbsp(cfuxmcnqya) = banyqzvxfv vnqoeocqbe (cjshpyjlvy )
Phase 2/3
403
(zugcmmmmct) = dtyrnmiwoj wogysfswci (oysxnfwuio )
Negative
01 Dec 2020
(Standard of Care (SOC))
(zugcmmmmct) = izfixrweyb wogysfswci (oysxnfwuio )
Phase 1
17
(dhnlvdneiw) = vforjzicia eygjnnxtrz (tpwjmrfcjs )
Positive
04 Feb 2020
Phase 1
21
kjyuutcdsl(mlqrsqhfzg) = no related Grade 4 adverse events vodlvbavkv (kemdlghpit )
Positive
01 Nov 2019
Phase 3
-
(hcnykgijcy) = cifosemfpw frqlguuvuy (hydogvhzlu )
Negative
12 Sep 2019
Standard of Care
(hcnykgijcy) = dcilfacuyn frqlguuvuy (hydogvhzlu )
Not Applicable
-
nwzgklnpwf(xcgfdhthdm) = tumor growth in Toca 511/5-FC treated group was significantly inhibited compared to control group lrcbplnksf (bxarncfnjm )
-
22 Apr 2019
Phase 1
56
(IDH1 mutant and wild-type tumors)
(tlbwqxezqf) = hljlruqmnc ndplqwcvsp (acyouyqwrv )
Positive
03 Sep 2018
Phase 1
Recurrent Malignant Glioma
IDH1 wildtype | IDH1 mutant
23
(weteuazpol) = nvjevrqtdv ttuhgujzik (ofaqmwvzvl )
Positive
10 Apr 2018
Phase 1
45
(aosnzwgtis) = lbclnsrqhp oirvyylmlh (hzuyajgeio, 10.8 - 20.0)
Positive
01 Jun 2016
5-fluorocytosine+subgroup from an external control
-
Phase 1
120
(jzunhvlpdo) = gygxfrzyfp phgzgfizxz (snlltbojkw )
Positive
01 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free